Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Tamar Tadmor, Toby A. Eyre, Ohad Benjamini, Arvind Chaudhry, Juan Shen, Siyang Leng, Mohammed Z. H. Farooqui, David Lavie

Blood (2024) 144 (Supplement 1): 1875.2.

https://doi.org/10.1182/blood-2024-198731

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Blood (2024) 144 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2024-203269

Published: 2024

Journal Articles

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz, Osnat Bairey, Reut Harel, Nadav Sarid, Tsofia Levi, Ofir Wolach, Yair Herishanu

Blood (2024) 144 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2024-205236

Published: 2024

Journal Articles

A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz, Osnat Bairey, Reut Harel, Tsofia Inbar, Ofir Wolach, Yair Herishanu

Blood (2023) 142 (Supplement 1): 4640.

https://doi.org/10.1182/blood-2023-185569

Published: 2023

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL

Ohad Benjamini, Tamar Tadmor, Abraham Avigdor, Rotem Gershon, Limor Klike, Nofar Atari, Bayan Abdelkader, Michal Mandelboim, Galia Rahav

Blood (2022) 140 (Supplement 1): 9900–9901.

https://doi.org/10.1182/blood-2022-167353

Published: 2022

Journal Articles

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Gilad Itchaki, Ohad Benjamini, Mor Levi, Anatoly Nemets, Shay Yeganeh, Mahdi Assaly, Anna Gourevitch, Revital Saban, Moshe E Gatt, Pia Raanani, Iuliana Vaxman

Blood (2022) 140 (Supplement 1): 11981–11982.

https://doi.org/10.1182/blood-2022-163009

Published: 2022

Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Blood (2022) 140 (Supplement 1): 228–230.

https://doi.org/10.1182/blood-2022-156070

Published: 2022

Journal Articles

Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma

Meirav Kedmi, Elena Ribakovsky, Ohad Benjamini, Avichai Shimoni, Abraham Avigdor

Blood (2022) 140 (Supplement 1): 12071–12072.

https://doi.org/10.1182/blood-2022-158742

Published: 2022

Journal Articles

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu, Galia Rahav, Shai Levi, Andrei Braester, Gilad Itchaki, Osnat Bairey, Najib Dally, Lev Shvidel, Tomer Ziv-Baran, Aaron Polliack, Tamar Tadmor, Ohad Benjamini, on behalf of the Israeli CLL Study Group

Blood (2022) 139 (5): 678–685.

https://doi.org/10.1182/blood.2021014085

Published: 2022

Includes: Supplemental data

Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Blood (2021) 138 (Supplement 1): 70.

https://doi.org/10.1182/blood-2021-148666

Published: 2021

Journal Articles

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Rosa Ruchlemer, Uri Abadi, Lev Shvidel, Andrei Braester, Raanan Cohen, Neta Frankel, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini

Blood (2021) 138 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2021-146504

Published: 2021

Journal Articles

Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Gilad Itchaki, Lior Rokach, Ohad Benjamini, Osnat Bairey, Adi Sabag, Helly Vernitsky, Hila Cohen, Shahar Rotem, Uri Elia, Pia Raanani, Erez Bar-Haim, Tamar Tadmor

Blood (2021) 138 (Supplement 1): 638.

https://doi.org/10.1182/blood-2021-150796

Published: 2021

Journal Articles

A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jonathan Canaani, MD, Ivetta Danilesko, MD, Noga Shem-Tov, MD, Maya Zlotnick, MD, Kira Lozinsky, Ohad Benjamini, Ronit Yerushalmi, MD, Meital Nagar, PhD, Chen Dor, PhD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135947

Published: 2020

Journal Articles

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Ohad Benjamini, Avichai Shimoni, MD, Michal Besser, PhD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Drorit Grizim Merkel, MD, Tamar Tadmor, MD, David Lavie, MD, Riva Fineman, MD, Elad Jacobi, MD, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138904

Published: 2020

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Guy Bitansky, Elena Vasilev, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD, Meirav Kedmi, MD

Blood (2019) 134 (Supplement_1): 1534.

https://doi.org/10.1182/blood-2019-125218

Published: 2019

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Meirav Kedmi, MD, Elena Ribakovsy, MD, Ohad Benjamini, MD, Ginette Schiby, MD, Iris Barshack, MD, Stephen P Raskin, MD, Yael Eshet, MD, Ramit Mehr, PhD, Guy Bitansky, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2018) 132 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2018-99-111658

Published: 2018

NARROW

Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only